Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345318 · ClinicalTrials.gov registry record · Phase 2
B0151005 Open-Label Extension Study
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
NCT01345318 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 191 participants.
The verdict
NCT01345318, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
Study Summary
This is a multi-center Phase 2, open label, safety extension study in subjects with moderate to severe CD who are anti-TNF inadequate responders. Subjects eligible for this study will have completed the 12-week induction period of study B0151003 and will be enrolled as either responders or non responders.
Interventions
- BIOLOGICAL PF-04236921
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345318
The ClinicalTrials.gov registry entry for NCT01345318 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04236921 is the first listed.
NCT01345318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01345318 about?
NCT01345318 is a clinical study titled "B0151005 Open-Label Extension Study". This is a multi-center Phase 2, open label, safety extension study in subjects with moderate to severe CD who are anti-TNF inadequate responders. Subjects eligible for this study will have completed the 12-week induction period of study B0151003 and will be enrolled as either responders or non respo...
What is the current status of trial NCT01345318?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2011-06. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01345318?
The interventions under investigation include: PF-04236921 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01345318?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.